TGFβ1-IN-3

Cat. No.:	HY-151955
CAS No.:	2883813-58-7
Molecular Formula:	$C_{23}H_{30}N_4O_5$
Molecular Weight:	442.51
Target:	TGF-β Receptor
Pathway:	TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

TGFβ1-IN-3 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-3 can be used for idiopathic pulmonary fibrosis (IPF) research[1].

In Vitro

TGFβ1-IN-3 (compound 44) shows inhibitory effect against NIH-3T3 cells with an IC_{50} of 0.57 μM[1].
TGFβ1-IN-3 (compound 44; 10 μM; for 24 h) inhibits TGF-β1-induced abnormal activation of NIH-3T3 and A549 cells, as well as migration and epithelial-mesenchymal transition (EMT) of A549 cells[1].
TGFβ1-IN-3 (compound 44) could bind to STAT3, and able to interact with Ile659, and the hydrophilic group piperidine formed intermolecular forces with Ser636, Arg609, and Pro639. The nitrofuran of TGFβ1-IN-3 could interact with Lys658[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	NIH-3T3 or A549 cells
Concentration:	10 μM
Incubation Time:	24 h
Result:	Were able to inhibit TGF-β1-induced activation of fibroblasts in vitro.

In Vivo

TGFβ1-IN-3 (compound 44; 30-60 mg/kg; p.o; once daily; for 22 days) improves mouse lung function and slowsthe progression of IPF. TGFβ1-IN-3 could reverse the pulmonary fibrosis in treatment model[1].
Pharmacokinetic parameters of TGFβ1-IN-3 (compound 44) in rats[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (6-10 weeks) injected with Bleomycin for establishing pulmonary fibrosis model[1].
Dosage:	30 mg/kg, 60 mg/kg
Administration:	Orally administration; once daily; for 22 days
Result:	Could reverse the pulmonary fibrosis in treatment model.

REFERENCES

[1]. Xingping Su, et al. Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114918.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA